Neurobiology of Opioid Dependence: 2 - 2
Phase 2
Withdrawn
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00000193
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Behavioral, subjective, measures of naloxone-preci Phsyiological, neuroendocrine measures of naloxone
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of gamma hydroxybutyric acid in opioid withdrawal management?
How does gamma hydroxybutyric acid compare to clonidine or buprenorphine in treating opiate withdrawal symptoms?
Are there specific biomarkers that predict response to gamma hydroxybutyric acid in opioid-dependent patients?
What are the potential adverse events associated with gamma hydroxybutyric acid use in opioid withdrawal treatment?
What combination therapies or alternative compounds have been explored alongside gamma hydroxybutyric acid for opioid dependence?
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸New Haven, Connecticut, United States
VA Connecticut Healthcare System🇺🇸New Haven, Connecticut, United States